Introduction
============

Major depressive disorder (MDD) is characterized by symptoms including depressed mood and a loss of interest or pleasure in activities.[@b1-ndt-14-103] As a consequence of depressive symptoms, patients with MDD typically have impaired functioning across multiple domains, including work, social, and family functioning.[@b2-ndt-14-103],[@b3-ndt-14-103] For example, depressive symptoms are associated with reduced marital quality, reduced work performance, and lower earnings.[@b2-ndt-14-103]

Key goals for patients with MDD experiencing a depressive episode are remission and full recovery.[@b4-ndt-14-103],[@b5-ndt-14-103] Recovery should be considered in broad terms, encompassing work, social, and family functioning as well as improvement of depressive symptoms.[@b6-ndt-14-103],[@b7-ndt-14-103] Indeed, patients with MDD consider a return to normal levels of functioning as one of the most important factors in defining remission from depression.[@b8-ndt-14-103] Although numerous standardized assessments are available to monitor functioning outcomes in the clinic and in research, functioning scales are used less frequently and less consistently than symptom severity scales.[@b9-ndt-14-103] Furthermore, functioning may be less responsive to treatment than symptoms, meaning that functional improvement can lag behind symptomatic outcomes.[@b10-ndt-14-103],[@b11-ndt-14-103]

Despite being the mainstay of pharmacological treatment for MDD, more than half of patients do not respond to antidepressant treatment (ADT), as shown by the Sequenced Treatment Alternatives to Relieve Depression (STAR\*D) study.[@b12-ndt-14-103] Patients with inadequate response to ADT have a prolonged loss of functioning and a lower likelihood of employment than those patients who do respond.[@b13-ndt-14-103],[@b14-ndt-14-103] Treatment strategies for patients with inadequate response to an optimized dose of ADT include switching to another antidepressant, combining the initial antidepressant with a second antidepressant that has a different mode of action, or augmenting the antidepressant with a non-antidepressant drug.[@b4-ndt-14-103],[@b15-ndt-14-103]--[@b18-ndt-14-103] Of the various options for augmentation, second-generation antipsychotics are best supported by the evidence.[@b19-ndt-14-103] However, the effects of different adjunctive therapies on patient functioning have not been consistently studied, and it is not clear whether existing measures of functioning are useful among patients with MDD and inadequate response to ADT.

A recent systematic review investigated the effect of ADT (selective serotonin reuptake inhibitors, serotonin--norepinephrine reuptake inhibitors, other antidepressants, and psychotherapies such as cognitive behavior therapy \[CBT\]) on functional outcomes in MDD.[@b20-ndt-14-103] The review, which excluded clinical studies of adjunctive pharmacotherapies, concluded that functioning improves together with depressive symptoms, but that functional deficits often remain, even among patients who achieve symptomatic remission.[@b20-ndt-14-103] Given the importance of functioning to the overall well-being of patients, the aim of the present systematic literature review was to determine if self-rated functional measures are informative in randomized placebo-controlled studies of adjunctive therapy in patients with MDD and inadequate response to ADT.

Methods
=======

This systematic review adheres to PRISMA.[@b21-ndt-14-103]

Eligibility criteria
--------------------

Studies were included if they were published, randomized, placebo-controlled studies of adjunctive therapy to ADT in patients with MDD and inadequate response to at least one ADT, and reported a self-rated scale of functioning. The literature search was performed on 8 March 2017. Reports were limited to those published on or after 1 January 1990. No language exclusions were applied.

Search strategy
---------------

The aim of the initial top-level search strategy was to identify studies that satisfied three criteria: 1) the study included patients with MDD; 2) the study was of antidepressant augmentation (with any pharmacological or non-pharmacological approach, such as CBT or deep brain stimulation); and 3) the study included a placebo or sham control group. The US National Library of Medicine's MEDLINE database was searched, via PubMed, using the terms: (depress\* OR MDD) AND (adjunct\* OR "add-on" OR augment\* OR resist\* OR refractory OR inadequate OR incomplete OR suboptimal) AND (placebo).

Following the initial search it became apparent that these terms were likely to miss some publications of olanzapine--fluoxetine combination (OFC) studies. OFC is indicated for the treatment of treatment-resistant depression in the US,[@b22-ndt-14-103] and, due to its availability as a single tablet, has been tested against fluoxetine with no need for placebo. Consequently, a second search was performed on 21 March 2017 to capture OFC studies, using the terms: (depress\* OR MDD) AND ((olanzapine AND fluoxetine) OR OFC).

Study selection
---------------

Following the top-level database searches, duplicates were excluded and records were screened to exclude unsuitable articles based on titles and abstracts ([Figure 1](#f1-ndt-14-103){ref-type="fig"}). At this stage, studies were not excluded based on a lack of functioning outcomes, because these are often secondary outcomes not mentioned in abstracts.

After screening, full-text articles for the remaining records were assessed for eligibility, defined as meeting all of the following criteria: 1) the study included patients with MDD; 2) the patients had inadequate response (by any definition) to at least one ADT; 3) the study investigated an adjunctive therapy to ADT; 4) the study included a placebo or sham control group (or a fluoxetine control group, for OFC); 5) the study was a randomized controlled trial or a post hoc analysis of a randomized controlled trial; and 6) the study reported self-rated functioning scale (or subscale) outcomes. Any self-rated functioning scale was eligible, defined as a scale that reflects the user's actual behavior in the world and is assessed in ways that emphasize doing, performing, maintaining, etc (this is distinct from quality of life -- a measure based on self-perception and context with an emphasis on satisfaction, contentment, or enjoyment in various aspects of life).[@b9-ndt-14-103] Eligibility assessment was performed in duplicate by two reviewers (split between CPW, CE and JARM), and disagreements were resolved by consensus.

Data extraction
---------------

The following data were extracted for each study, where available: 1) the definition of inadequate response to ADT, both historical (prior to study enrollment) and prospective/ongoing (during the study); 2) the adjunctive treatment (type, dose, and duration); 3) the number of randomized patients; 4) the primary efficacy endpoint and whether or not it was met (in order that failed or negative studies might be identified); 5) the name of the self-rated functioning scale/subscale/items used; 6) self-rated functioning scale scores at baseline (ie, randomization to adjunctive therapy) and the mean change from baseline to the study endpoint (including error measurements, *p*-values versus placebo, and patient numbers); 7) the setting; and 8) the source of funding. Published data were supplemented with data from ClinicalTrials.gov and study protocols/reports, where available. One reviewer extracted the data from included studies (CPW) and a second reviewer checked the extracted data (CE). Disagreements were resolved by checking the original data source. To assess the risk of bias in individual studies, one reviewer (CPW) judged the adequacy of randomization, blinding, and outcome reporting for each study.

Results
=======

Study characteristics
---------------------

A total of 2,090 discrete records were identified and screened ([Figure 1](#f1-ndt-14-103){ref-type="fig"}).

Of the 293 full-text articles assessed for eligibility, 26 articles were included, of which 20 reported one or more primary study, and six reported post hoc analyses of already identified studies. In total, these articles described 26 different studies, the characteristics of which are shown in [Table 1](#t1-ndt-14-103){ref-type="table"}. Five of the post hoc analyses were pooled analyses of aripiprazole, and are not discussed further.[@b23-ndt-14-103]--[@b27-ndt-14-103] The sixth post hoc analysis reported self-rated functioning data from a risperidone study in more detail than in the primary manuscript.[@b28-ndt-14-103] No sources of bias were identified in individual studies.

The only self-rated functioning scale used in the included studies was the Sheehan Disability Scale (SDS),[@b49-ndt-14-103]--[@b51-ndt-14-103] which was always a secondary or exploratory outcome. The SDS comprises three visual analog scales on which patients self-rate the extent to which symptoms have disrupted their: 1) work/studies (including paid and unpaid volunteer work and training); 2) social life or leisure activities; and 3) family life or home responsibilities. Each of these items is scored from 0 (not at all) to 10 (extremely). Patients can skip the work/studies item if they have not worked/studied in the last week for reasons unrelated to their disorder (eg, retirement); the instructions are unclear for patients who have stopped working because of their depression. The majority of studies calculated the SDS total score, obtained by summing the scores for the three items (range 0 to 30).[@b37-ndt-14-103]--[@b43-ndt-14-103],[@b45-ndt-14-103],[@b46-ndt-14-103],[@b48-ndt-14-103] If the work/studies item was unrated, as was the case for 10%--35% of patients (in studies where patient numbers by item were available), it was generally unclear whether these patients were excluded from the SDS total score, or whether the SDS total score was calculated by imputing the mean of the other two items in place of the work/studies item. One study calculated the SDS sum of items 2 and 3 score (range 0 to 20), since a large proportion of patients (25%--35%) had no work/studies rating.[@b33-ndt-14-103] Six studies calculated the SDS mean score, obtained by taking an average of the item scores for all items that were rated (range 0 to 10).[@b29-ndt-14-103]--[@b32-ndt-14-103],[@b34-ndt-14-103],[@b35-ndt-14-103] Finally, four studies did not specify how SDS scores were calculated.[@b36-ndt-14-103],[@b44-ndt-14-103],[@b47-ndt-14-103]

As can be seen in [Table 1](#t1-ndt-14-103){ref-type="table"}, 13 different adjunctive agents were used across the studies, of which five were second-generation antipsychotics. All were short-term studies (6--12 weeks), except for one 52-week study. The minimum number of ADTs (historical plus prospective) to which patients were required to show inadequate response prior to randomization ranged from one to two. Definitions of inadequate response varied, from "investigator judgment", to strict definitions with qualifying scores on multiple rating scales at multiple time points.

Efficacy
--------

Each of the second-generation antipsychotics (aripiprazole, brexpiprazole, cariprazine, olanzapine as OFC \[pooled data\], and risperidone) had at least one dose that met the primary efficacy endpoint of their respective studies (improvement of depressive symptoms, measured by either Montgomery--Åsberg Depression Rating Scale total score or 17-item Hamilton Depression Rating Scale total score; [Table 1](#t1-ndt-14-103){ref-type="table"}).[@b29-ndt-14-103]--[@b32-ndt-14-103],[@b34-ndt-14-103],[@b35-ndt-14-103],[@b37-ndt-14-103],[@b47-ndt-14-103],[@b48-ndt-14-103] The combination of buprenorphine and samidorphan also met its primary efficacy endpoint at one dose.[@b36-ndt-14-103] All other agents failed to meet the primary efficacy endpoint of their respective studies, and were therefore failed or negative studies.

A summary of the SDS results from the included studies is given in [Table 2](#t2-ndt-14-103){ref-type="table"}. Baseline SDS scores were similar between treatment groups in each study. All groups (active and control) improved numerically from baseline to endpoint, as measured by the SDS total or SDS mean. Most active treatments showed a numerically greater improvement than placebo (except for dexmecamylamine, which had inconsistent results). However, the majority of agents, and studies, failed to show a statistically significant benefit versus placebo on the SDS total or SDS mean. Only four agents demonstrated efficacy (*p*\<0.05 versus placebo) on the SDS total or SDS mean in at least one study: aripiprazole, brexpiprazole, edivoxetine, and risperidone. A large variation in placebo response was seen between studies.

Considering the individual SDS items, only one agent (aripiprazole) in one study had a statistically significant benefit on the SDS work/studies item. The study in question (Kamijima et al)[@b32-ndt-14-103] investigated two doses (3 mg and 3--15 mg) of adjunctive aripiprazole in a 6-week randomized treatment phase, and both doses showed a benefit on the work/studies item. Three other studies of aripiprazole were included in the review; none of these showed efficacy on the SDS work/studies item, despite having almost identical designs to Kamijima et al.

On the SDS social life item, aripiprazole, brexpiprazole, edivoxetine, olanzapine (as OFC), and risperidone showed a benefit over placebo (*p*\<0.05) in at least one study. On the SDS family life item, a benefit (*p*\<0.05) was observed for aripiprazole, brexpiprazole, cariprazine, olanzapine (as OFC), and risperidone in at least one study.

Discussion
==========

This review of 26 randomized placebo-controlled studies showed that, of the 13 adjunctive agents identified, only aripiprazole, brexpiprazole, edivoxetine, and risperidone statistically significantly improved functioning versus placebo, as measured by the SDS total or mean, in patients with MDD and inadequate response to at least one ADT. In a previous meta-analysis of adjunctive second-generation antipsychotics in MDD, which was conducted prior to the availability of brexpiprazole data, only aripiprazole and risperidone were found to provide a benefit based on a composite endpoint of patient-reported functioning and quality of life.[@b52-ndt-14-103] Furthermore, a systematic review in patients with MDD who received ADT (but no adjunctive pharmacotherapy) found that many patients, particularly partial responders, continued to experience functional impairments after treatment, highlighting an unmet need in MDD.[@b20-ndt-14-103]

Other than edivoxetine, a selective norepinephrine reuptake inhibitor, the only agents to show statistically significant benefits on any SDS items in the present review were second-generation antipsychotics. Of these agents, aripiprazole and brexpiprazole have an indication for the adjunctive treatment of MDD, and OFC has an indication for the treatment of treatment-resistant depression (all in the US).[@b22-ndt-14-103],[@b53-ndt-14-103],[@b54-ndt-14-103] The development of edivoxetine as an adjunctive treatment for MDD was halted in 2013 because it failed to meet the primary endpoint in three Phase 3 studies.[@b55-ndt-14-103] Indeed, more than half of the adjunctive agents identified in this review failed to meet the primary efficacy endpoint of their respective studies. Nonetheless, the findings of this review suggest that the SDS as a whole is a useful scale to track changes in functioning among patients with inadequate response to ADTs, and that adjunctive second-generation antipsychotics or edivoxetine may improve functioning in such patients.

The SDS was the only self-rated measure of functional impairment that was used in the retrieved records. This observation is in line with a meta-analysis of second-generation antipsychotics for the adjunctive treatment of MDD.[@b52-ndt-14-103] Indeed, the SDS appears to be the most widely used functioning measure in studies of MDD.[@b20-ndt-14-103] The SDS is considered to be a reliable and valid measure of functioning impairment, originally developed in 1981 for use in treatment outcome studies in psychiatry.[@b49-ndt-14-103]--[@b51-ndt-14-103] To the authors' knowledge, no minimal clinically important difference has been established for the SDS. Sheehan selected the three items of work/studies, social life, and family life after reviewing other impairment instruments and consulting with patients and colleagues.[@b51-ndt-14-103] In general, all three items, including the work/studies item, are sensitive to treatment effects across a variety of psychological disorders.[@b51-ndt-14-103] In the present review, however, in the population of patients with MDD and inadequate response to ADTs, only aripiprazole had a statistically significant benefit on the SDS work/studies item, and this was only in one study out of four. Thus, where a benefit was observed on the SDS total or mean, this was generally driven by improvement on the social life and family life items.

There are several possible reasons for a lack of effect on the work/studies item in this population. Since the work/studies item is not rated for patients who are not working, one possibility is that the studies were underpowered to measure this item. In general, as shown in a US nationwide survey of patients with MDD, inadequate responders to ADT (based on self-reports) are less likely to be employed than responders.[@b14-ndt-14-103] Unfortunately, the majority of studies in the present review did not separate out the number of patients who rated each item of the SDS. Where such data were available, 10%--35% of patients across the studies with a rating on the social life and family life items did not rate the work/studies item. Thus, the power to show a difference between treatment groups was reduced for the work/studies item compared with the other items.

Nevertheless, 65%--90% of patients did rate the work/studies item, and therefore were in employment or studying. In general, studies have shown that people with depression who are in employment are less severely ill than those who are unemployed.[@b56-ndt-14-103],[@b57-ndt-14-103] Thus, on average, the subset of patients who rated the work/studies item may be less severely ill than the total population in each study. Meta-analyses have investigated the question of whether or not antidepressant efficacy increases with baseline illness severity, with varying results.[@b58-ndt-14-103],[@b59-ndt-14-103] If, as some have suggested, antidepressants are more efficacious in more severely ill patients, then the drug--placebo difference may be expected to be greater in the total population (ie, on the social life and family life items) than in the subset of patients in employment (ie, on the work/studies item).

Finally, it is possible that the studies were too short to show a benefit on the work/studies item. With a few exceptions, the included studies assessed functioning after 6 or 8 weeks of adjunctive treatment. In general, job performance deficits can still remain after 18 months among patients whose depressive symptoms have improved,[@b60-ndt-14-103] and patients with inadequate response to ADT are particularly at risk of persisting impairment.[@b61-ndt-14-103] Thus, acute studies may not be able to detect a benefit in occupational functioning in this population of inadequate responders. Only one of the included studies was a long-term study, and, over 52 weeks, adjunctive dexmecamylamine did not show a notable difference to adjunctive placebo on the SDS total.[@b41-ndt-14-103] However, dexmecamylamine failed as an adjunctive agent in MDD, having shown no differences to placebo on the primary efficacy outcome in four acute studies,[@b39-ndt-14-103],[@b40-ndt-14-103] and thus no benefit on the SDS might be expected.

Recent literature has acknowledged the difficulty in using the work/studies item among populations with a high proportion of non-workers, and attempts have been made to modify the SDS accordingly. Sonne et al proposed a rewording of the first item from "work/studies" to "work/daily tasks", so that patients without a job could still rate the item.[@b62-ndt-14-103] Similarly, Bech reported a modified version of the SDS in which the work/studies item was replaced by an overall rating, "Your daily activities all things considered".[@b63-ndt-14-103]

The present review is limited because it only considered published literature, leading to a risk of publication bias (as positive studies are more likely to be published than failed or negative studies). However, even with the risk of publication bias, fewer than a third of the included studies reported a treatment benefit on the SDS. In addition, the review is limited since MEDLINE (via PubMed) was the only database searched. Nonetheless, the 26 studies identified had a consistent message, that the work/studies item is less informative in this population than the other two items.

Conclusion
==========

The SDS, a self-rated functional measure, is informative in acute randomized placebo-controlled studies of adjunctive therapy in patients with MDD and inadequate response to ADT. However, the item that measures work performance may be less relevant to this population than the items that measure social and family life.
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###### 

Characteristics of included studies

  Reference (ClinicalTrials.gov identifier)                                   Adjunctive treatment                                            Adjunctive treatment duration                                                  Randomized patients                                           Inadequate response to (current episode)                     Inadequate response definition   Primary efficacy measure                                                                                                                                                                                                                                                                                          Setting                   Source of funding                                                                                           
  --------------------------------------------------------------------------- --------------------------------------------------------------- ------------------------------------------------------------------------------ ------------------------------------------------------------- ------------------------------------------------------------ -------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------- ----------------------------------------------------------------------------------------------------------- ---------------------------------------------------
  Berman et al, 2007[@b29-ndt-14-103] (NCT00095823)                           Aripiprazole 2--20 mg                                           6 weeks                                                                        362                                                           1--3 historical ADTs + 1 prospective SSRI/SNRI               \<50% improved on ATRQ           \<50% reduction in HAM-D~17~ total score from start of prospective treatment to week 8; HAM-D~17~ total score ≥14 and CGI-I score ≥3 at week 8                                                                                                                                                                    MADRS total               24 outpatient sites in the US                                                                               Bristol-Myers Squibb and Otsuka
  Marcus et al, 2008[@b30-ndt-14-103] (NCT00095758)                           Aripiprazole 2--20 mg                                           6 weeks                                                                        381                                                           1--3 historical ADTs + 1 prospective SSRI/SNRI               \<50% improved on ATRQ           \<50% reduction in HAM-D~17~ total score from start of prospective treatment to week 8; HAM-D~17~ total score ≥14 and CGI-I score ≥3 at week 8                                                                                                                                                                    MADRS total               36 outpatient sites in the US                                                                               Bristol-Myers Squibb and Otsuka
  Berman et al, 2009[@b31-ndt-14-103] (NCT00105196)                           Aripiprazole 2--20 mg                                           6 weeks                                                                        349                                                           1--3 historical ADTs + 1 prospective SSRI/SNRI               \<50% improved on ATRQ           \<50% reduction in HAM-D~17~ total score from start of prospective treatment to week 8; HAM-D~17~ total score ≥14 at week 8; CGI-I score ≥3 at weeks 6 and 8                                                                                                                                                      MADRS total               36 outpatient sites in the US                                                                               Bristol-Myers Squibb and Otsuka
  Kamijima et al, 2013[@b32-ndt-14-103] (NCT00876343)                         Aripiprazole 3 mg/3--15 mg                                      6 weeks                                                                        586                                                           1--3 historical ADTs + 1 prospective ADT                     Not specified                    \<50% reduction in HAM-D~17~ total score from start of prospective treatment to week 8; HAM-D~17~ total score ≥14 and CGI-I score ≥3 at week 8[c](#tfn3-ndt-14-103){ref-type="table-fn"}                                                                                                                          MADRS total               169 sites in Japan                                                                                          Otsuka
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Quiroz et al, 2016[@b33-ndt-14-103] (NCT01437657)                           Basimglurant MR 0.5 mg/1.5 mg                                   6 weeks                                                                        333                                                           1--3 historical ADTs (1 ongoing SSRI/SNRI)                   Investigator judgment            MADRS total score ≥25 and CGI-S score ≥4 at screening[d](#tfn4-ndt-14-103){ref-type="table-fn"}                                                                                                                                                                                                                   MADRS total               59 outpatient sites in Chile, Europe, Japan, Mexico, and the US                                             Hoffmann-La Roche
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Thase et al, 2015[@b34-ndt-14-103] (NCT01360645)                            Brexpiprazole 2 mg                                              6 weeks                                                                        379                                                           1--3 historical ADTs + 1 prospective SSRI/SNRI               \<50% improved on ATRQ           \<50% reduction in HAM-D~17~ total score from start of prospective treatment to week 8; HAM-D~17~ total score ≥14 at week 8; \<50% reduction in MADRS total score from start of prospective treatment to weeks 2, 4, 6, and 8; CGI-I score ≥3 at weeks 2, 4, 6, and 8[e](#tfn5-ndt-14-103){ref-type="table-fn"}   MADRS total               59 outpatient sites in Canada, Europe, and the US                                                           Otsuka and Lundbeck
  Thase et al, 2015[@b35-ndt-14-103] (NCT01360632)                            Brexpiprazole 1 mg/3 mg                                         6 weeks                                                                        677                                                           1--3 historical ADTs + 1 prospective SSRI/SNRI               \<50% improved on ATRQ           \<50% reduction in HAM-D~17~ total score from start of prospective treatment to week 8; HAM-D~17~ total score ≥14 at week 8; \<50% reduction in MADRS total score from start of prospective treatment to weeks 2, 4, 6, and 8; CGI-I score ≥3 at weeks 2, 4, 6, and 8[e](#tfn5-ndt-14-103){ref-type="table-fn"}   MADRS total               92 outpatient sites in Canada, Europe, Russia, and the US                                                   Otsuka and Lundbeck
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Fava et al, 2016[@b36-ndt-14-103] (NCT01500200)                             Buprenorphine + samidorphan 2 mg + 2 mg/8 mg + 8 mg             Stage 1: 5 weeks; stage 2: 5 weeks[f](#tfn6-ndt-14-103){ref-type="table-fn"}   142                                                           1--2 historical ADTs (1 ongoing)                             \<50% improved on ATRQ           For entry into stage 2[f](#tfn6-ndt-14-103){ref-type="table-fn"}: \<50% reduction in HAM-D~17~ total score from start of stage 1 to week 5; HAM-D~17~ total score ≥14 at week 5                                                                                                                                   HAM-D~17~ total           31 sites in the US                                                                                          Alkermes
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Durgam et al, 2016[@b37-ndt-14-103] (NCT01469377)                           Cariprazine 1--2 mg/2--4.5 mg                                   8 weeks                                                                        819                                                           1--2 historical ADTs (1 ongoing)                             Not specified                    ATHF resistance rating ≥3 with global confidence ≥3 at screening[e](#tfn5-ndt-14-103){ref-type="table-fn"}                                                                                                                                                                                                        MADRS total               76 outpatient sites in Europe and the US                                                                    Forest Laboratories (Allergan) and Gedeon Richter
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Fava et al, 2015[@b38-ndt-14-103] (NCT01098240)                             CP-601,927 2--4 mg                                              6 weeks                                                                        162                                                           1--3 historical ADTs + 1 prospective SSRI                    \<50% improved on ATRQ           \<50% reduction in HAM-D~17~ total score from start of prospective treatment to week 8; HAM-D~17~ total score ≥16 at week 8                                                                                                                                                                                       MADRS total               25 outpatient sites in the US                                                                               Pfizer
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Vieta et al, 2014[@b39-ndt-14-103] (NCT01157078, NCT01180400)               Dexmecamylamine 2--8 mg (2 studies)                             8 weeks                                                                        319, 295                                                      0--1 historical ADTs + 1 prospective SSRI/SNRI               Not specified                    \<50% reduction in HAM-D~17~ total score from start of prospective treatment to week 8; HAM-D~17~ total score ≥16 and CGI-S score ≥4 at week 8                                                                                                                                                                    MADRS total               70 outpatient sites in India and the US; 80 outpatient sites in Europe                                      AstraZeneca and Targacept
  Möller et al, 2015[@b40-ndt-14-103] (NCT01153347, NCT01197508)              Dexmecamylamine 0.2 mg/1 mg/2 mg/4 mg/8 mg (across 2 studies)   8 weeks                                                                        641, 696                                                      0--1 historical ADTs + 1 prospective SSRI/SNRI               Not specified                    \<50% reduction in HAM-D~17~ total score from start of prospective treatment to week 8; HAM-D~17~ total score ≥16 and CGI-S score ≥4 at week 8                                                                                                                                                                    MADRS total               114 outpatient sites in India and the US; 132 outpatient sites in Europe, South Africa, and South America   AstraZeneca and Targacept
  Tummala et al, 2015[@b41-ndt-14-103] (NCT01152554)                          Dexmecamylamine 2--8 mg                                         52 weeks                                                                       813 (769 de novo[g](#tfn7-ndt-14-103){ref-type="table-fn"})   0--1 historical ADTs + 1 prospective SSRI/SNRI               Not specified                    De novo patients[g](#tfn7-ndt-14-103){ref-type="table-fn"}: HAM-D~17~ total score ≥10 and CGI-S score ≥3 at week 6 of prospective treatment                                                                                                                                                                       Not applicable (safety)   115 outpatient sites in the US                                                                              AstraZeneca
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Ball et al, 2014[@b42-ndt-14-103] (NCT00840034)                             Edivoxetine 6--18 mg                                            8 weeks                                                                        227                                                           1 ongoing SSRI                                               Not applicable                   Investigator judgment at screening; \<25% reduction in QIDS-SR~16~ score from start of adjunctive placebo phase to week 2                                                                                                                                                                                         MADRS total               25 outpatient sites in the US                                                                               Eli Lilly and Company
  Ball et al, 2016[@b43-ndt-14-103] (NCT01173601, NCT01187407, NCT01185340)   Edivoxetine 6 mg/12 mg/12--18 mg/18 mg (across 3 studies)       8 weeks                                                                        701, 689, 449                                                 1 ongoing SSRI                                               Not applicable                   Investigator judgment at screening and start of adjunctive placebo phase; \<25% reduction in MADRS total score from start of adjunctive placebo phase to week 3; MADRS total score ≥14 at week 3                                                                                                                  MADRS total               Multiple outpatient sites in Australia, Europe, Japan, Russia, South Africa, and the US                     Eli Lilly and Company
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Barbee et al, 2011[@b44-ndt-14-103] (NCT00901407)                           Lamotrigine 100--400 mg                                         10 weeks                                                                       96                                                            ≥1 historical ADT + 1 prospective paroxetine/paroxetine CR   Not specified                    HAM-D~17~ total score ≥15 at week 8 of prospective treatment                                                                                                                                                                                                                                                      MADRS total               19 sites in the US                                                                                          GlaxoSmithKline
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Sanacora et al, 2017[@b45-ndt-14-103] (NCT01482221)                         Lanicemine 50 mg/100 mg (IV regimen)                            12 weeks (primary analysis at week 6)                                          302                                                           ≥1 historical ADT (1 ongoing)                                Investigator judgment            Investigator judgment                                                                                                                                                                                                                                                                                             MADRS total               49 outpatient sites in Chile, Europe, South Africa, and the US                                              AstraZeneca
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Richards et al, 2016[@b46-ndt-14-103] (NCT01436149, NCT01436162)            Lisdexamfetamine dimesylate 20--70 mg (2 studies)               8 weeks                                                                        404, 426                                                      0--2 historical ADTs + 1 prospective SSRI/SNRI               Not specified                    \<50% reduction in MADRS total score from start of prospective treatment to week 8; MADRS total score ≥18 at week 8                                                                                                                                                                                               MADRS total               76 sites in Canada, Europe, Mexico and the US; 94 sites in Europe, South Africa, and the US                 Shire
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Thase et al, 2007[@b47-ndt-14-103] (NCT00035321)                            Olanzapine 6--18 mg (as OFC; 2 studies pooled)                  8 weeks                                                                        605 (pooled)                                                  1 historical ADT + 1 prospective fluoxetine                  Investigator judgment            \<25% reduction in HAM-D~17~ total score from start of prospective treatment to week 8; HAM-D~17~ total score ≥18 at week 8; ≤15% reduction in HAM-D~17~ total score from week 7 to week 8                                                                                                                        MADRS total               Multiple outpatient sites in Canada and the US                                                              Eli Lilly and Company
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Mahmoud et al, 2007[@b48-ndt-14-103] (NCT00095134)                          Risperidone 1--2 mg                                             6 weeks                                                                        274                                                           1 ongoing ADT                                                Not applicable                   CGI-S score ≥4 and CDS score ≥20 at week 4 of prospective phase                                                                                                                                                                                                                                                   HAM-D~17~ total           75 outpatient sites in the US                                                                               Ortho-McNeil-Janssen

**Notes:**

"Historical" describes an ADT that was discontinued prior to study enrollment.

"Prospective" describes an ADT that was initiated during the study, whereas "ongoing" describes an ADT that was initiated prior to study enrollment and was continued during the study.

The manuscript states that any one of these criteria is sufficient; however, by comparison with the other aripiprazole studies, we assume this is an error.

In addition, where available, a patient-rated MADRS total score ≥23 at screening, with a permitted discrepancy of ≤7 points versus the clinician-rated MADRS total score.

Revised criteria following a protocol amendment.

Two-stage study design: 1) patients were randomized to placebo or active treatment; 2) placebo non-responders in stage 1 were re-randomized to placebo or active treatment.

Study also rolled-over a small number of patients from two acute studies (NCT01157078 and NCT01153347).

**Abbreviations:** ADT, antidepressant treatment; ATHF, Antidepressant Treatment History Form; ATRQ, Massachusetts General Hospital Antidepressant Treatment Response Questionnaire; CDS, Carroll Depression Scale; CGI-I/S, Clinical Global Impressions -- Improvement/Severity of illness; CR, controlled release; HAM-D~17~, 17-item Hamilton Depression Rating Scale; IV, intravenous; MADRS, Montgomery--Åsberg Depression Rating Scale; MR, modified release; OFC, olanzapine--fluoxetine combination; QIDS-SR~16~, 16-item Quick Inventory of Depressive Symptomatology (Self-Report); SNRI, serotonin--norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor.

###### 

Change from baseline to endpoint in self-rated functioning scale scores (for the population who received ≥1 dose of randomized treatment and had ≥1 post-baseline efficacy evaluation)

  Reference                                   Treatment arm                                         SDS summary score                                          SDS work/studies                                        SDS social life                                                SDS family life                                                                                                                                                                                                                                                                                                                                                                                                
  ------------------------------------------- ----------------------------------------------------- ---------------------------------------------------------- ------------------------------------------------------- -------------------------------------------------------------- -------------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------- --
  **Aripiprazole**                                                                                  **SDS mean**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  Berman et al, 200729                        Placebo                                               164                                                        5.4 (0.2)[a](#tfn10-ndt-14-103){ref-type="table-fn"}    164                                                            −0.7 (0.2)                                                                                                             −0.7 (0.3)[b](#tfn11-ndt-14-103){ref-type="table-fn"}                                                           −0.8 (0.2)                                                                                                      −0.5 (0.2)                                              
  2--20 mg                                    167                                                   5.7 (0.2)[a](#tfn10-ndt-14-103){ref-type="table-fn"}       167                                                     −1.1 (0.2)                                                     0.055                                                          −0.7 (0.2)[c](#tfn12-ndt-14-103){ref-type="table-fn"}   0.98                                                    −1.4(0.2)                                               0.030                                                   −1.1 (0.2)                                              0.017                                                   
  Marcus et al, 2008[@b30-ndt-14-103]         Placebo                                               168                                                        5.4 (0.2)[a](#tfn10-ndt-14-103){ref-type="table-fn"}    168                                                            −0.7 (0.2)                                                                                                             −0.4 (0.2)[d](#tfn13-ndt-14-103){ref-type="table-fn"}                                                           −0.6 (0.2)[e](#tfn14-ndt-14-103){ref-type="table-fn"}                                                           −1.0 (0.2)[e](#tfn14-ndt-14-103){ref-type="table-fn"}   
  2--20 mg                                    180                                                   5.1 (0.2)[a](#tfn10-ndt-14-103){ref-type="table-fn"}       180                                                     −1.3 (0.2)                                                     0.012                                                          −0.5 (0.2)[f](#tfn15-ndt-14-103){ref-type="table-fn"}   0.62                                                    −1.4 (0.2)[g](#tfn16-ndt-14-103){ref-type="table-fn"}   0.002                                                   −1.8 (0.2)[g](#tfn16-ndt-14-103){ref-type="table-fn"}   0.002                                                   
  Berman et al, 2009[@b31-ndt-14-103]         Placebo                                               160                                                        5.9 (0.2)[a](#tfn10-ndt-14-103){ref-type="table-fn"}    160                                                            −0.8 (0.2)                                                                                                             −0.7 (0.3)[h](#tfn17-ndt-14-103){ref-type="table-fn"}                                                           −0.7 (0.2)                                                                                                      −0.8 (0.2)                                              
  2--20 mg                                    160                                                   5.7 (0.2)[a](#tfn10-ndt-14-103){ref-type="table-fn"}       160                                                     −1.2 (0.2)                                                     0.075                                                          −0.8 (0.3)[i](#tfn18-ndt-14-103){ref-type="table-fn"}   0.79                                                    −1.2 (0.2)                                              0.052                                                   −1.4 (0.2)                                              0.037                                                   
  Kamijima et al, 2013[@b32-ndt-14-103]       Placebo                                               195                                                        5.3 (0.1)[a](#tfn10-ndt-14-103){ref-type="table-fn"}    193                                                            −0.5 (0.1)                                                                                                             −0.4 (0.1)                                                                                                      −0.6 (0.1)                                                                                                      −0.3 (0.1)                                              
  3 mg                                        197                                                   5.0 (0.1)[a](#tfn10-ndt-14-103){ref-type="table-fn"}       197                                                     −1.0 (0.1)                                                     0.001                                                          −0.9 (0.1)                                              0.003                                                   −1.1 (0.1)                                              0.003                                                   −0.9 (0.1)                                              0.003                                                   
  3--15 mg                                    194                                                   5.0 (0.1)[a](#tfn10-ndt-14-103){ref-type="table-fn"}       193                                                     −1.0 (0.1)                                                     \<0.001                                                        −1.0 (0.1)                                              \<0.001                                                 −1.2 (0.1)                                              \<0.001                                                 −0.9 (0.1)                                              0.003                                                   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  **Basimglurant MR**                         **SDS sum of items 2 and 3**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Quiroz et al, 2016[@b33-ndt-14-103]         Placebo                                               109[j](#tfn19-ndt-14-103){ref-type="table-fn"}             13.2 (3.7)                                              109                                                            −5.1 (0.6)                                                                                                                                                                                                                                                                                                                                                                                                     
  0.5 mg                                      112[j](#tfn19-ndt-14-103){ref-type="table-fn"}        13.8 (4.0)                                                 112                                                     −5.1 (0.6)                                                     0.94                                                                                                                                                                                                                                                                                                                                                                                                           
  1.5 mg                                      111[j](#tfn19-ndt-14-103){ref-type="table-fn"}        13.5 (3.6)                                                 111                                                     −6.4 (0.6)                                                     0.09                                                                                                                                                                                                                                                                                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  **Brexpiprazole**                                                                                 **SDS mean**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  Thase et al, 2015[@b34-ndt-14-103]          Placebo                                               191[j](#tfn19-ndt-14-103){ref-type="table-fn"}             6.3 (2.1)                                               178                                                            −0.9 (0.2)                                                                                                             −1.0 (0.2)                                                                                                      −1.0 (0.2)                                                                                                      −0.7 (0.2)                                              
  2 mg                                        188[j](#tfn19-ndt-14-103){ref-type="table-fn"}        6.0 (2.0)                                                  175                                                     −1.4 (0.2)                                                     0.035                                                          −1.1 (0.2)                                              0.61                                                    −1.6 (0.2)                                              0.022                                                   −1.3 (0.2)                                              0.011                                                   
  Thase et al, 2015[@b35-ndt-14-103]          Placebo                                               221[k](#tfn20-ndt-14-103){ref-type="table-fn"}             5.6 (1.9)                                               203                                                            −0.8 (0.2)                                                                                                             −0.7 (0.2)                                                                                                      −0.9 (0.2)                                                                                                      −0.8 (0.2)                                              
  1 mg                                        226[k](#tfn20-ndt-14-103){ref-type="table-fn"}        5.9 (2.0)                                                  211                                                     −1.3 (0.2)                                                     0.016                                                          −1.1 (0.2)                                              0.082                                                   −1.3 (0.2)                                              0.035                                                   −1.3 (0.2)                                              0.019                                                   
  3 mg                                        230[k](#tfn20-ndt-14-103){ref-type="table-fn"}        5.7 (2.2)                                                  213                                                     −1.3 (0.2)                                                     0.019                                                          −0.9 (0.2)                                              0.30                                                    −1.4 (0.2)                                              0.028                                                   −1.4 (0.2)                                              0.0077                                                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  **Buprenorphine + samidorphan**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Fava et al, 2016[@b36-ndt-14-103]           Placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  2 mg + 2 mg                                                                                                                                                                                                                                                                         NS                                                                                                                                                                                                                                                                                                                                                                                                             
  8 mg + 8 mg                                                                                                                                                                                                                                                                         NS                                                                                                                                                                                                                                                                                                                                                                                                             
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  **Cariprazine**                                                                                   **SDS total**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Durgam et al, 2016[@b37-ndt-14-103]         Placebo                                               264                                                        18.5 (4.7)                                              264                                                            −6.6 (0.5)                                                                                                                                                                                                                                                                                                                                             −2.3                                                    
  1--2 mg                                     273                                                   18.7 (4.7)                                                 273                                                     −7.7 (0.5)                                                     0.24                                                                                                                   NS                                                                                                              NS                                                                                                              NS                                                      
  2--4.5 mg                                   271                                                   18.8 (4.8)                                                 271                                                     −8.0 (0.5)                                                     0.11                                                                                                                   NS                                                                                                              NS                                                      −2.9                                                    0.014                                                   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  **CP-601, 927**                                                                                   **SDS total**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Fava et al, 2015[@b38-ndt-14-103]           Placebo                                               85                                                         18.5 (5.3)                                              85                                                             −5.7 (8.2)[l](#tfn21-ndt-14-103){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                                          
  *2*--4 mg                                   77                                                    19.0 (5.9)                                                 77                                                      −6.6 (8.0)[l](#tfn21-ndt-14-103){ref-type="table-fn"}          NS                                                                                                                     NS                                                                                                              NS                                                                                                              NS                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  **Dexmecamylamine**                         **SDS total**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  Vieta et al, 2014[@b35-ndt-14-103]          Placebo                                                                                                                                                                  151                                                            −5.5 (0.7)                                                                                                             −1.7 (0.2)[m](#tfn22-ndt-14-103){ref-type="table-fn"}                                                           −1.9 (0.2)                                                                                                      −2.0 (0.3)                                              
  2--8 mg                                                                                                                                                      143                                                     −6.1 (0.7)                                                     0.42                                                           −2.0 (0.2)[n](#tfn23-ndt-14-103){ref-type="table-fn"}   0.21                                                    −1.9 (0.2)                                              0.93                                                    −2.1 (0.3)                                              0.76                                                    
  Placebo                                                                                                                                                      142                                                     −5.8 (0.5)                                                                                                                    −1.8 (0.2)[o](#tfn24-ndt-14-103){ref-type="table-fn"}                                                           −1.9 (0.2)                                                                                                      −2.0 (0.2)                                                                                                      
  2--8 mg                                                                                                                                                      138                                                     −5.8 (0.5)                                                     0.96                                                           −2.2 (0.3)[p](#tfn25-ndt-14-103){ref-type="table-fn"}   0.20                                                    −2.0 (0.2)                                              0.76                                                    −1.9 (0.2)                                              0.62                                                    
  Möller et al, 2015[@b40-ndt-14-103]         Placebo                                                                                                                                                                  153                                                            −4.9 (0.6)                                                                                                             −1.7 (0.2)[q](#tfn26-ndt-14-103){ref-type="table-fn"}                                                           −1.9 (0.2)                                                                                                      −1.6 (0.2)                                              
  1 mg                                                                                                                                                         152                                                     −5.5 (0.6)                                                     0.42                                                           −1.7 (0.2)[r](#tfn27-ndt-14-103){ref-type="table-fn"}   0.95                                                    −1.9 (0.2)                                              0.92                                                    −1.9 (0.2)                                              0.21                                                    
  4 mg                                                                                                                                                         148                                                     −5.5 (0.6)                                                     0.49                                                           −1.8 (0.2)[s](#tfn28-ndt-14-103){ref-type="table-fn"}   0.87                                                    −1.9 (0.2)                                              0.97                                                    −1.8 (0.2)                                              0.34                                                    
  8 mg                                                                                                                                                         149                                                     −4.5 (0.7)                                                     0.60                                                           −1.7 (0.2)[t](#tfn29-ndt-14-103){ref-type="table-fn"}   0.79                                                    −1.6(0.2)                                               0.24                                                    −1.6 (0.2)                                              0.97                                                    
  Placebo                                                                                                                                                      172                                                     −7.1 (0.6)                                                                                                                    −2.1 (0.2)[u](#tfn30-ndt-14-103){ref-type="table-fn"}                                                           −2.4 (0.2)                                                                                                      −2.3 (0.2)                                                                                                      
  0.2 mg                                                                                                                                                       171                                                     −6.1 (0.6)                                                     0.18                                                           −2.0 (0.2)[v](#tfn31-ndt-14-103){ref-type="table-fn"}   0.91                                                    −2.1 (0.2)                                              0.25                                                    −2.0 (0.2)                                              0.17                                                    
  2 mg                                                                                                                                                         168                                                     −6.3 (0.6)                                                     0.33                                                           −1.8 (0.2)[w](#tfn32-ndt-14-103){ref-type="table-fn"}   0.45                                                    −2.2 (0.2)                                              0.50                                                    −2.1 (0.2)                                              0.40                                                    
  8 mg                                                                                                                                                         163                                                     −6.2 (0.6)                                                     0.27                                                           −1.9 (0.2)[x](#tfn33-ndt-14-103){ref-type="table-fn"}   0.66                                                    −2.2 (0.2)                                              0.44                                                    −2.0 (0.2)                                              0.20                                                    
  Tummala et al, 2015[@b41-ndt-14-103]        Placebo                                                                                                                                                                  70                                                             −7.4 (7.5)[l](#tfn21-ndt-14-103){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                                          
  2--8 mg                                                                                                                                                      185                                                     −7.0 (7.9)[l](#tfn21-ndt-14-103){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                                                                                                         
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  **Edivoxetine**                                                                                   **SDS total[y](#tfn34-ndt-14-103){ref-type="table-fn"}**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  Ball et al, 2014[@b42-ndt-14-103]           Placebo                                               71[k](#tfn20-ndt-14-103){ref-type="table-fn"}              19.2 (6.8)                                              68                                                             −2.6                                                                                                                   −0.4                                                                                                            −1.0                                                                                                            −1.0                                                    
  6--18 mg                                    67[k](#tfn20-ndt-14-103){ref-type="table-fn"}         17.9 (6.9)                                                 63                                                      −6.0                                                           0.039                                                          −1.9                                                    0.10                                                    −2.1                                                    0.046                                                   −1.9                                                    0.11                                                    
  Ball et al, 2016[@b43-ndt-14-103]           Placebo                                               P: 690[k](#tfn20-ndt-14-103){ref-type="table-fn"}          P: 18.1 (6.1)                                           240                                                            −4.5 (0.4)                                                                                                                                                                                                                                                                                                                                                                                                     
  12 mg                                       E: 1,149[k](#tfn20-ndt-14-103){ref-type="table-fn"}   E: 18.2 (5.8)                                              231                                                     −5.4 (0.4)                                                     NS                                                                                                                                                                                                                                                                                                                                                                                                             
  18 mg                                       (pooled)                                              (pooled)                                                   230                                                     −5.3 (0.4)                                                     NS                                                                                                                                                                                                                                                                                                                                                                                                             
  Placebo                                                                                                                                                      231                                                     −4.3 (0.4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  6 mg                                                                                                                                                         226                                                     −6.3 (0.4)                                                     ≤0.05                                                                                                                                                                                                                                                                                                                                                                                                          
  12--18 mg                                                                                                                                                    232                                                     −5.3 (0.4)                                                     NS                                                                                                                                                                                                                                                                                                                                                                                                             
  Placebo                                                                                                                                                      219                                                     −4.4 (0.5)                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  12--18 mg                                                                                                                                                    230                                                     −4.5 (0.5)                                                     NS                                                                                                                                                                                                                                                                                                                                                                                                             
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  **Lamotrigine**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Barbee et al, 2011[@b44-ndt-14-103]         Placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  100--400 mg                                                                                                                                                                                                                                                                         NS                                                                                                                                                                                                                                                                                                                                                                                                             
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  **Lanicemine (IV regimen)**                 **SDS total**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  Sanacoraet al, 2017[@b45-ndt-14-103]        Placebo                                                                                                                                                                  97                                                             −6.9 (1.0)                                                                                                                                                                                                                                                                                                                                                                                                     
  50 mg                                                                                                                                                        101                                                     −7.1 (1.0)                                                     0.89                                                                                                                                                                                                                                                                                                                                                                                                           
  100 mg                                                                                                                                                       100                                                     −6.9 (1.0)                                                     0.99                                                                                                                                                                                                                                                                                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  **Lisdexamfetamine dimesylate**             **SDS total**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  Richardset al, 20I6[@b46-ndt-14-103]        Placebo                                               198                                                        15.6 (5.7)                                              164                                                            −4.3 (−5.3, −3.3)[z](#tfn35-ndt-14-103){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                                   
  20--70 mg                                   198                                                   15.9 (6.0)                                                 162                                                     −4.7 (−5.6, −3.7)[z](#tfn35-ndt-14-103){ref-type="table-fn"}   0.58                                                                                                                   NS                                                                                                              NS                                                                                                              NS                                                      
  Placebo                                     213                                                   16.8 (5.8)                                                 189                                                     −4.3 (−5.2, −3.4)[z](#tfn35-ndt-14-103){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                                                                                                  
  20--70 mg                                   209                                                   16.8 (5.3)                                                 180                                                     −4.9 (−5.8, −4.0)[z](#tfn35-ndt-14-103){ref-type="table-fn"}   0.35                                                                                                                   NS                                                                                                              NS                                                                                                              NS                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  **Olanzapine (as OFC; 2 studies pooled)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  Thase et al, 2007[@b47-ndt-14-103]          Fluoxetine                                                                                                                                                               203                                                                                                                                                                                                                                                                                                   −1.1 (2.6)[l](#tfn21-ndt-14-103){ref-type="table-fn"}                                                           −1.2 (2.6)[l](#tfn21-ndt-14-103){ref-type="table-fn"}   
  6--18 mg                                                                                                                                                     198                                                                                                                                                                                                                                           0.46                                                    −1.6 (2.8)[l](#tfn21-ndt-14-103){ref-type="table-fn"}   0.027                                                   −1.7 (2.7)[l](#tfn21-ndt-14-103){ref-type="table-fn"}   0.047                                                   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  **Risperidone**                                                                                   **SDS total**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Mahmoud et al, 2007[@b48-ndt-14-103]        Placebo                                               113                                                        20.2 (0.6)[a](#tfn10-ndt-14-103){ref-type="table-fn"}   101                                                            −3.9                                                                                                                   −0.8                                                                                                            −1.5                                                                                                            −1.4                                                    
  1--2 mg                                     110                                                   19.9 (0.6)[a](#tfn10-ndt-14-103){ref-type="table-fn"}      100                                                     −7.6                                                           \<0.001                                                        −1.7                                                    0.12                                                    −2.9                                                    \<0.001                                                 −2.5                                                    \<0.001                                                 
  Pandina et al, 2009[@b28-ndt-14-103]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

**Notes:** Highlighted cells indicate *p*≤0.05 versus placebo.

SE.

n=130.
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n=170.

n=142.

n=181.

n=126.

n=115.

For the population who received ≥1 dose of randomized treatment

For the randomized population.

SD.
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n=115.
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n=132.

n=123.

n=134.

n=137.

n=141.

n=140.

n=126.

If the work/studies item was missing, the mean of the other two items was imputed to calculate the total score.

95% CI.

**Abbreviations:** E, edivoxetine; IV, intravenous; MR, modified release; NS, not statistically significant (and *p*-value not reported); OFC, olanzapine--fluoxetine combination; P, placebo; SDS, Sheehan Disability Scale.
